Written by While the market for Single Photon Emission Computed Tomography (SPECT) in Italy continues to grow, industry stakeholders face operational, economic, and technological shifts. As outlined in the latest Italy Single Photon Emission Computed Tomography Market Forecast, overcoming radioisotope supply chain vulnerabilities and integrating artificial intelligence into workflow management will be essential to expanding SPECT’s role in Italian clinical care over the coming decade.
Managing Isotope Supply Chain Risks
A significant challenge confronting Italian nuclear medicine departments is the supply stability of Technetium-99m (Tc-99m), derived from its parent isotope Molybdenum-99 (Mo-99). Because Mo-99 production relies on a limited number of global research reactors, unscheduled reactor maintenance can cause regional supply shortages. Italian diagnostic centers are increasingly adopting optimized radioisotope scheduling tools and exploring alternative production routes, such as cyclotron-produced Tc-99m, to mitigate supply disruptions.
Role of Artificial Intelligence and Deep Learning
The integration of Artificial Intelligence (AI) and deep learning algorithms is transforming SPECT diagnostic workflows across Italian medical centers:
Image Reconstruction: AI-driven reconstruction algorithms reduce image noise, enabling fast scan protocols and lower radiotracer doses without compromising image clarity.
Automated Quantification: Machine learning tools assist nuclear medicine physicians by automatically segmenting organs and calculating quantitative metrics, such as myocardial blood flow or bone lesion burden.
Workflow Automation: AI tools streamline patient positioning and scan planning, helping Italian hospitals process higher patient volumes efficiently.
Competition with PET Imaging and Market Outlook
While Positron Emission Tomography (PET) continues to gain ground in oncology due to its higher spatial resolution, SPECT retains a cost-effective, versatile advantage in routine cardiology, neurology, and skeletal imaging. As new targeted SPECT radiopharmaceuticals enter clinical trials and hybrid SPECT/CT technology becomes more accessible, the Italian SPECT market is positioned for steady, long-term growth, remaining a vital pillar of nuclear diagnostic medicine across Italy.